Compare AstraZeneca plc (AZN) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Bank of Nova Scotia — how do they compare? AstraZeneca plc trades at $157.96 (market cap $248.14B), while Bank of Nova Scotia trades at $89.03 (market cap $108.32B). The key difference: AstraZeneca plc is far larger — about 2.3× Bank of Nova Scotia's market cap, and Bank of Nova Scotia pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| AZN | BNS | |
|---|---|---|
Market Cap | $248.14B | $108.32B |
Sector | Health | Financials |
52-Week High | $209.48 | $90.29 |
52-Week Low | $147.06 | $56.41 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 3.64% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
